Marta Castiglia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5410633/publications.pdf

Version: 2024-02-01

394390 434170 1,041 32 19 31 citations g-index h-index papers 33 33 33 2117 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Liquid biopsies in lung cancer: The new ambrosia of researchers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 539-546.	7.4	123
2	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget, 2016, 7, 60712-60722.	1.8	103
3	Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?. Analytical Cellular Pathology, 2015, 2015, 1-19.	1.4	80
4	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Critical Reviews in Oncology/Hematology, 2014, 89, 300-313.	4.4	68
5	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. Scientific Reports, 2018, 8, 13379.	3.3	66
6	Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer. Advances in Experimental Medicine and Biology, 2016, 937, 207-228.	1.6	55
7	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983992.	3.2	48
8	ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it. Translational Lung Cancer Research, 2014, 3, 250-61.	2.8	44
9	Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool. Journal of Visualized Experiments, 2016, , .	0.3	43
10	Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094237.	3.2	37
11	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. Oncotarget, 2016, 7, 47821-47830.	1.8	36
12	Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis. Current Cancer Drug Targets, 2018, 18, 697-705.	1.6	34
13	Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines. BioMed Research International, 2013, 2013, 1-8.	1.9	32
14	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)â€"Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes. Cancers, 2020, 12, 1158.	3.7	30
15	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987465.	3.2	27
16	Dietary restriction: could it be considered as speed bump on tumor progression road?. Tumor Biology, 2016, 37, 7109-7118.	1.8	24
17	Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?. Oncotarget, 2016, 7, 29321-29332.	1.8	23
18	EGFR inhibition in NSCLC: New findings…. and opened questions?. Critical Reviews in Oncology/Hematology, 2017, 112, 126-135.	4.4	22

#	Article	IF	Citations
19	Spheroids from adiposeâ€derived stem cells exhibit an miRNA profile of highly undifferentiated cells. Journal of Cellular Physiology, 2018, 233, 8778-8789.	4.1	20
20	Nintedanib in NSCLC: evidence to date and place in therapy. Therapeutic Advances in Medical Oncology, 2016, 8, 188-197.	3.2	19
21	A headlight on liquid biopsies: a challenging tool for breast cancer management. Tumor Biology, 2016, 37, 4263-4273.	1.8	18
22	Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. Cancers, 2020, 12, 534.	3.7	15
23	Adipose tissue, angiogenesis and angio-MIR under physiological and pathological conditions. European Journal of Cell Biology, 2019, 98, 53-64.	3.6	14
24	Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. Journal of Molecular Pathology, 2021, 2, 173-196.	1.2	14
25	Cell quality evaluation with gene expression analysis of spheroids (3D) and adherent (2D) adipose stem cells. Gene, 2021, 768, 145269.	2.2	13
26	An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. Expert Opinion on Drug Safety, 2019, 18, 485-496.	2.4	10
27	Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180.	3.2	7
28	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. Journal of Clinical Pathology, 2022, 75, 416-421.	2.0	6
29	Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110497.	3.2	3
30	Cell-free DNA and exoDNA analysis in metastatic colorectal cancer patients (mCRC) Journal of Clinical Oncology, 2020, 38, e16093-e16093.	1.6	1
31	Targeted Therapy. UNIPA Springer Series, 2021, , 181-206.	0.1	0
32	KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis Journal of Clinical Oncology, 2016, 34, 3565-3565.	1.6	0